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The structure of recombinant Aquifex aeolicus UDP-3-O-acyl-N-acetylglucos-
amine deacetylase (LpxC) in complex with UDP has been determined to a
resolution of 2.2 A ˚ . Previous studies have characterized the binding sites of the
fatty-acid and sugar moieties of the substrate, UDP-(3-O-hydroxymyristoyl)-
N-acetylglucosamine, but not that of the nucleotide. The uracil-binding site is
constructed from amino acids that are highly conserved across species.
Hydrophobic associations with the Phe155 and Arg250 side chains in
combination with hydrogen-bonding interactions with the main chain of
Glu154 and the side chains of Tyr151 and Lys227 position the base. The
phosphate and ribose groups are directed away from the active site and interact
with Arg137, Lys156, Glu186 and Arg250. The orientation of the phosphate-
ribose tail is not conducive to catalysis, perhaps owing to the position of an
inhibitory Zn
2+. However, based on the position of uracil revealed in this study
and on the previously reported complex of LpxC with an inhibitor, a model is
proposed for substrate binding.
1. Introduction
A unique biochemical pathway in Gram-negative bacteria leads to
the production of lipopolysaccharide (LPS), a major component of
the outer membrane of these organisms. LPS contributes to bacterial
resistance to antibiotics (Nikaido, 2003) and hyperstimulation of the
host immune system (Cohen, 2002; Lopez-Bojorquez et al., 2004). It
has three structural components: core polysaccharide, O-antigen and
lipid A, a fatty-acid (FA) substituted phosphorylated glucosamine
disaccharide. Lipid A is required for both bacterial viability (Raetz &
Whitﬁeld, 2002) and modulation of the host immune system (Galanos
et al., 1985).
Several of the enzymes involved in the synthesis of lipid A are
essential for the growth and viability of Gram-negative bacteria
(Raetz & Whitﬁeld, 2002) and represent targets for chemotherapy.
One such enzyme, UDP-3-O-acyl-N-acetylglucosamine deacetylase
(LpxC), catalyzes the ﬁrst committed step in the synthesis of lipid A
(Raetz & Whitﬁeld, 2002). Inhibition of LpxC in vivo has led to
successful treatment of infection in mice (Kline et al., 2002; Onishi et
al., 1996). In both Escherichia coli and Aquifex aeolicus, LpxC
deacetylates UDP-(3-O-hydroxymyristoyl)-N-acetylglucosamine
(Jackman et al., 2001; Young et al., 1995). LpxC is a metalloenzyme
that uses Zn
2+ to activate a nucleophilic attack by water on the amide
of the N-acetylglucosamine (GlcNAc) moiety of the substrate (Fig. 1;
Jackman et al., 1999); like other bacterial metalloamidases, a second
inhibitory zinc-binding site is present (Jackman et al., 1999; Whit-
tington et al., 2003). LpxC presents an + fold with no known
mammalian homologues (Whittington et al., 2003). This uniqueness,
its essentiality and the previous success in enzyme inhibition make
LpxC an attractive target for structure-based drug design.
The elements required by LpxC to bind and catalyze substrate
include a zinc-binding motif, UDP-binding and GlcNAc-binding sites
and a hydrophobic cavity to bind FA. Structural and biochemical
studies have identiﬁed HKX(L,F)D as the zinc-binding motif in LpxC
(Jackman et al., 2001; Whittington et al., 2003) and several inhibitors
containing hydroxamate groups exploit the presence of the divalent
cation. Crystallographic studies of LpxC have elucidated a hydro-
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FA (Hernick et al., 2005; Whittington et al., 2003). The presence of a
longer FA moiety on the GlcNAc results in a higher binding afﬁnity
to LpxC and is required for efﬁcient catalysis (Jackman et al., 1999,
2000; Whittington et al., 2003). The inhibitor 1,5-anhydro-2-C-
(carboxymethyl-N-hydroxyamide)-2-deoxy-3-O-myristoyl-d-glucitol
(TU-514; Fig. 1) is a substrate-analogue inhibitor that has been used
to characterize the GlcNAc-binding site of LpxC (Coggins et al., 2003,
2005; Gennadios et al., 2006). TU-514 exploits the zinc-coordination
and FA-binding and GlcNAc-binding sites of LpxC and the result is
an inhibitor with nanomolar afﬁnity for the enzyme (Jackman et al.,
2000). Inhibitor design would beneﬁt from including UDP-recogni-
tion elements, but presently this binding site remains uncharacter-
ized. Here, we present a crystallographic analysis of a complex of
A. aeolicus LpxC with UDP that allows us to describe the molecular
recognition of UDP in the nucleotide-binding site of the enzyme.
2. Materials and methods
2.1. Sample preparation
Aconstruct identical to that previously described by Whittington et
al. (2003) was used. This produces a truncated version of the enzyme
which also contains a cysteine-to-alanine mutation that has been
found to reduce aggregation. Brieﬂy, lpxC was ampliﬁed from
genomic DNA of A. aeolicus (strain VF5) using the primers
CATATGGGATTAGAAAAGACGGTTAAAGAG and GGATCC-
TTATCAACGAGTAAGTTTTTGTTTCTTTG, which contained an
N-terminal NdeI and a C-terminal BamHI restriction site, respec-
tively, as indicated in bold. The PCR product, which encodes residues
1–271 of the protein, was ligated into pCR-Blunt II-TOPO using the
Zero Blunt TOPO Cloning Kit (Invitrogen). The lpxC 272–282
insert was subsequently ligated into NdeI- and BamHI-digested
pET21a (Novagen). The C181A mutation was inserted using diver-
gent PCR techniques (Higuchi et al., 1988). The integrity of this
construct, pET21a-lpxC C181A 272–282, was veriﬁed by DNA
sequencing.
The plasmid containing modiﬁed lpxC was transformed into
Rosetta(DE3) pLysS (Novagen) for expression. A single colony was
used to inoculate 10 ml of enriched media (Nair et al., 1991)
containing carbenicillin (50 mg l
 1) and chloramphenicol (12 mg l
 1)
and was grown overnight at 310 K. The overnight culture was diluted
(1:100) into 1 l fresh medium and grown at 310 K until the A600
reached 0.6. Expression was induced at 298 K with 1 mM isopropyl
-d-thiogalactopyranoside and the medium was supplemented with
0.1 mM ZnSO4 at this point. The cells were harvested approximately
16 h later by centrifugation (Beckman JS-4.2, 3480g at 277 K for
60 min) and stored at 253 K.
The cell pellet was resuspended in 20 ml 20 mM NaCl, 20 mM Tris
pH 8 and 50 mM EDTA and lysed using a constant cell disrupter
(One Shot model, Constant Systems Ltd). The soluble fraction was
separated by centrifugation (Beckman JA-25.50, 48 400g at 277 K for
30 min), passed through a 0.2 mm ﬁlter and loaded onto a 5 ml HiTrap
Q FF column (GE Healthcare). A linear gradient from 20 to 500 mM
NaCl was used to elute the protein. The fractions containing LpxC
were pooled, treated with 20 mM EDTA pH 8 and dialyzed into
50 mM NaCl, 20 mM Tris pH 7.7 overnight. The sample was applied
onto a 5 ml HisTrap HP column (GE Healthcare) charged with
ZnSO4 and the protein was eluted using a combination of step and
linear gradients from 15 to 500 mM imidazole. Fractions containing
LpxC were pooled and further puriﬁed by gel-ﬁltration chromato-
graphy (Superdex 75, GE Healthcare) in 150 mM NaCl, 25 mM
HEPES pH 7.5 and 0.5 mM ZnSO4.1 0m M magnesium acetate was
added to the sample, which was subsequently concentrated to 184 mM
as determined using a theoretical molar extinction coefﬁcient of
22 900 M
 1 cm
 1. Purity was ascertained by SDS–PAGE and matrix-
assisted laser desorption ionization–time-of-ﬂight mass spectrometry.
The experimentally determined weight of the protein was
30 811.6 Da, which agrees with the predicted weight of the protein in
the absence of the initial methionine (30 810.3 Da).
2.2. Crystallization and data collection
Crystals of LpxC were grown by hanging-drop vapour diffusion at
293 K using 1 ml protein solution (184 mM) and 1 ml of a reservoir
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Figure 1
(a) The reaction catalyzed by LpxC. (b) The inhibitor TU-514.solution containing 8% PEG 6000, 100 mM Tris pH 8.5 and 300 mM
NaCl. Crystals were harvested and subsequently soaked for 24 h in a
pre-equilibrated vapour-diffusion drop initially composed of 0.5 ml
500 mM UDP-N-acetylglucosamine (UDP-GlcNAc) in gel-ﬁltration
buffer and 0.5 ml reservoir solution containing 17% PEG 6000,
100 mM Tris pH 8.5 and 150 mM NaCl. The crystals were ﬂash-cooled
to  100 K (Oxford Cryosystems) in a solution consisting of 17%
PEG 6000, 100 mM Tris pH 8.5, 150 mM NaCl and 20% glycerol.
Data were collected at the European Synchrotron Radiation Facility
onbeamline ID23-2 using a MAR CCD 225 detector.Atotal of80  of
data were collected in 1  oscillations at a wavelength of 0.873 A ˚ using
an exposure time of 2 s. The data were integrated using MOSFLM
(Leslie, 1992) as implemented in CCP4 (Collaborative Computa-
tional Project, Number 4, 1994) and then scaled and merged using
SCALA (Evans, 1997). Signiﬁcant radiation damage was evident on
this undulator beamline and only the ﬁrst 60 images were used.
Statistics are given in Table 1.
2.3. Structural determination and refinement
The crystal is isomorphous with previously reported structures
(Gennadios et al., 2006; Whittington et al., 2003) and contains two
molecules per asymmetric unit. A single molecule of LpxC (PDB
code 1p42) was used in molecular-replacement calculations
(MOLREP; Vagin & Teplyakov, 2000) and two initial solutions were
identiﬁed. These molecules will be referred to as chains A and B.
Reﬁnement involved rounds of electron-density and difference
density map inspection and model building using the program Coot
(Emsley & Cowtan, 2004) interspersed with restrained maximum-
likelihood reﬁnement (REFMAC5; Murshudov et al., 1997). The
placement of ligand and water molecules completed the reﬁnement.
Noncrystallographic symmetry restraints were not imposed during
reﬁnement. The N-terminal methionine is absent and three residues
at the C-terminus are disordered in both monomers. Statistics for the
reﬁned structure are presented in Table 1. An overlay of C
 positions
for residues 2–266 of our model with the starting model gave an
r.m.s.d. of 0.19 A ˚ for chain A and 0.24 A ˚ for chain B.
2.4. Modelling the substrate
UDP-(3-O-hydroxymyristoyl)-N-acetylglucosamine
The crystal structure of LpxC with bound inhibitor TU-514 (PDB
code 2go4) was overlaid on the structure of LpxC with bound UDP.
The substrate was placed at the active site and manipulated using
Coot and O (Jones et al., 1991) such that the uracil and pyranose
moieties of the substrate overlaid with those of UDP and TU-514,
respectively. The geometry of the model was idealized in REFMAC5
using molecular restraints obtained from PRODRG (Schu ¨ttelkopf &
van Aalten, 2004).
3. Results and discussion
3.1. Overall structure
A detailed description of the LpxC structure has been published
(Whittington et al., 2003). In brief, LpxC displays an + fold
containing two domains, each consisting of a ﬁve-stranded -sheet
and two -helices. These domains are sandwiched together with both
sets of helices between the sheets (Fig. 2). The active site is located
between the domains at the -sheet interface. The enzyme has been
crystallized in the zinc-inhibited form, with two Zn
2+ ions present in
the active site. A third Zn
2 is located between -helix C, which ﬂanks
the active site, and the loop joining the small  domain to the
larger -sheet and is coordinated by residues His58 and His188, a
chloride and a water molecule (not shown). A fourth Zn
2+ is co-
ordinated by Gly2 and Glu120 of chain A and by Glu90 and His29 of
a symmetry-related chain B (not shown). This is a crystallization
artefact rather than an indication of oligomerization, as gel-ﬁltration
experiments clearly show the protein to be a monomer (data not
shown). Electron density was observed in the FA-binding cavity of
both chains and was modelled as myristic acid. In chain A the FA
directly binds the inhibitory Zn
2+, while in chain B the carboxylic acid
head extends away from the active site and is disordered over two
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Table 1
Crystallographic statistics.
Values in parentheses represent the highest resolution bin of approximate width 0.12 A ˚ .
Space group P61
Unit-cell parameters (A ˚ ) a = 101.76, c = 124.24
Resolution range (A ˚ ) 50.9–2.2
No. of observed/unique reﬂections 142119/36577
Wilson B (A ˚ 2) 23.7
Mosaic spread ( ) 0.27
Completeness (%) 99.0 (98.5)
Multiplicity 3.9 (3.9)
Rsym (%) 10.8 (47.5)
hI/(I)i 11.3 (3.6)
R factor (%) 16.8
Rfree (%) 22.5
R.m.s.d. from ideal values, bond lengths (A ˚ ) 0.01
R.m.s.d. from ideal values, bond angles ( ) 1.205






Ramachandran plot analysis (%)
Residues in most favoured regions 88.5
Residues in allowed regions 11.5
Residues in disallowed regions 0
Cruickshank DPI† (A ˚ ) based on Rfree 0.18
PDB code 2j65
† Diffraction-component precision index (Cruickshank, 1999).
Figure 2
Ribbon diagram of the LpxC–UDP complex. Domains I and II are shown in green
and wheat, respectively. Secondary structure is labelled according to previous
assignments (Whittington et al., 2003). UDP is depicted as spheres and myristic acid
as sticks. Activity-related Zn
2+ ions are depicted as grey spheres, with the inhibitory
ion labelled I. Ligand atoms are coloured as follows: C, black; O, red; N, blue; P,
yellow. Figs. 2, 3 and 4 were prepared with PyMOL (DeLano, 2002).positions (not shown). The FA was not added to the crystallization
solution and is likely to have been acquired from the expression
system. Similar FA binding has been observed in other LpxC struc-
tures (Gennadios et al., 2006; Whittington et al., 2003).
3.2. Nucleotide binding
Our current study, the crystal structure of the zinc-inhibited form
of LpxC in complex with UDP, provides structural details concerning
nucleotide binding for the ﬁrst time. The nucleotide-binding site is
located between strand 30 and helix A0 of domain II (Fig. 2). The
uracil moiety is well deﬁned in the electron density, with the ribose
and phosphates less so (Fig. 3). This clearly correlates with the
average B factor observed for each moiety: 58.9, 65.6 and 76.0 A ˚ 2 for
uracil, ribose and diphosphate, respectively. We were unable to model
the GlcNAc portion of the UDP-GlcNAc. This segment of the added
ligand may be disordered or missing owing to hydrolysis. The
presence of the inhibitory Zn
2+ at the entrance to the active-site
cavity (Fig. 2) may preclude GlcNAc binding, leading to nonspeciﬁc
association and disorder. Interestingly, the use of identical soaking
conditions with UDP rather than UDP-GlcNAc resulted in crystal
dissolution.
The uracil-binding pocket is mainly formed by residues contrib-
uted from 40, the 80--B0 turn and one face of -A0 (Figs. 2, 3 and 4).
The uracil is 10.5 A ˚ from the catalytic Zn
2+ (measured from O2) and
is placed in a hydrophobic patch where it forms a -bond with
Phe155. This is a highly conserved amino acid; in 241 of 248 assigned
LpxC sequences found in a range of databases this position is an
aromatic residue (Phe/Tyr/Trp). In the remaining seven sequences,
derived from Burkholderia species, a leucine occupies this position.
Phe155 is part of a hydrophobic patch that, along with Phe180 and
Phe182, is recognized as an afﬁnity determinant for binding to LpxC
(Coggins et al., 2005). Both uracil N3 and O2 are within hydrogen-
bonding distance of the side-chain hydroxyl of Tyr151, which forms
part of the / interface of the protein. In alignments of LpxC across
248 species, approximately 50% of all LpxC sequences have
phenylalanine, 25% have isoleucine, leucine or valine and 15% have
tyrosine at this position. This observation emphasizes the importance
of a hydrophobic side chain in deﬁning this part of the uracil-binding
pocket. It is possible that in the absence of a tyrosine hydroxyl group
a solvent could occupy this site and mediate interactions between the
base and the enzyme.
Additional hydrogen-bonding interactions hold the nucleotide in
the binding site. O4 accepts a hydrogen bond from the main-chain
amide of Glu154; this side chain, which is exposed on the surface of
the protein, does not appear to be important in organizing the
binding site despite a high level of conservation as either aspartate or
glutamate. The uracil O2 accepts a hydrogen bond donated from
Lys227 NZ. This residue is conserved in LpxC as either lysine or
arginine, where a similar hydrogen-bonding interaction is plausible.
Mutagenesis studies (McClerren et al., 2005) show Lys227 to be
critical for enzyme activity since a K227A mutant retains only 0.05%
activity of the wild-type LpxC. In the structure with the inhibitor
TU-514, a water-mediated hydrogen bond links the C-6 hydroxyl of
the inhibitor to the side chain of this lysine (Gennadios et al., 2006).
The ribose and phosphates are directed away from the active site in
a position that is inconsistent with the substrate orientation required
for catalysis. LpxC from A. aeolicus does not deacetylate UDP-
GlcNAc (Whittington et al., 2003) and poor penetration of this
molecule into the active site of the zinc-inhibited form is likely to be
expected. The ribose interacts with the side chains of Arg137 and
Glu185. This is a well conserved residue pairing in that a basic lysine
is often observed at the corresponding arginine position and the
glutamate is retained or replaced by aspartate or glutamine. The
-phosphate interacts with the basic side chains of Arg250 and
Lys156 (Fig. 3). The arginine is highly conserved, but not the lysine.
The current positions of the ribose and phosphates and interactions
with the enzyme may represent a conﬁguration adopted by substrate
as it binds in advance of catalysis or alternatively by product as it
vacates the catalytic centre.
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Figure 3
UDP-binding site and the omit difference electron-density map. The map has
coefﬁcients |Fo   Fc|, c and is contoured at 3.5. Fo represents the observed
structure factors, Fc the calculated structure factors and c the calculated phases
from which ligand contributions were omitted. Protein residues within 4 A ˚ of UDP
are labelled and putative hydrogen bonds (within 3.6 A ˚ ) are shown as black dashed
lines. Atoms are coloured as described in Fig. 2, with the C
 atoms of the protein
coloured salmon.
Figure 4
A model for substrate binding in the active site. LpxC is depicted as a van der Waals
surface. The experimental models of UDP and TU-514, derived from crystal
structures, provide the template to model the substrate. The ligands are shown as
sticks. The experimentally derived C atoms are coloured black and the modelled
substrate C atoms cyan. Conserved residues in the LpxC active site (at a level
of >60%) are coloured by type: histidines green, lysine blue, aspartate red,
threonine slate-blue, aromatic phenylalanines salmon, glycine and leucine magenta.
The catalytic Zn
2+ and a water molecule implicated in the mechanism are shown as
grey and marine spheres, respectively, and ligand atoms are depicted as in Figs. 2
and 3.3.3. Implications for substrate binding
We propose that the nucleotide-binding site observed in this study
represents the position that uracil adopts during substrate recogni-
tion and subsequently catalysis. Binding of the base involves highly
conserved residues, which when altered inﬂuence both binding and
enzyme activity (Coggins et al., 2005; McClerren et al., 2005). There is
a notable absence of conserved hydrogen bonds between the hexose
of the substrate analogue TU-514 and LpxC (Gennadios et al., 2006).
Isooxazoline-based inhibitors carrying carboxylate or phosphonate
head groups bind more tightly to E. coli LpxC if they contain an
aliphatic substituent (IC50 values of 4 mM with and >450 mM without;
Pirrung et al., 2002), suggesting that hexose–protein interactions do
not contribute signiﬁcantly to substrate binding. Therefore, inter-
actions between LpxC and the UDP and FA moieties of the substrate
are likely to contribute the most to ordering of the substrate during
catalysis. Using our experimentally derived uracil-binding site and a
GlcNAc-binding site based on the position of the pyranose in the
crystallographic model of LpxC with TU-514, a substrate model can
be constructed by varying the torsion angles between the uracil and
the ribose, in particular the glycosidic link between the base and
ribose, and the ribose and the phosphates while maintaining binding
of the FA within the hydrophobic cavity (Fig. 4). Note that the
inhibitory Zn
2+ was removed from the structural template prior to
modelling because it prevents access to thecatalytic Zn
2+. The r.m.s.d.
of atoms from uracil common to those of the substrate is 0.03 A ˚ and
the r.m.s.d. of the inhibitor pyranose atoms to those of the substrate is
0.08 A ˚ . The model places the functional groups in chemically plau-
sible positions for catalysis, supporting the conclusion that the uracil
placement we observe is biologically relevant. Our structure now
completes the picture of how LpxC recognizes substrate and imparts
information to support a structure-based approach to inhibitor
development.
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